Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naïve HIV-infected patients: II study of the abacavir/lamivudine/efavirenz haart regimen

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue 1, 2012, Pages 247-258

  Chini, M ^a   Tsoupras, Alexander B ^b   Mangafas, N ^a   Tsogas, N ^a   Papakonstantinou, V D ^b   Fragopoulou, E ^c   Antonopoulou, S ^c   Gargalianos, P ^d   Demopoulos, C A ^b   Lazanas, M C ^a  

^a RED CROSS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c HAROKOPIO UNIVERSITY   (Greece)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Abacavir; Cardiovascular Disease (CVD); Highly Active Anti Retroviral Therapy (HAART); Human Immunodeficiency Virus (HIV); Inflammation; Platelet Activating Factor (PAF)

Indexed keywords

ABACAVIR; ACYLTRANSFERASE; CHOLINEPHOSPHOTRANSFERASE; EFAVIRENZ; LAMIVUDINE; THROMBOCYTE ACTIVATING FACTOR; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ABACAVIR PLUS LAMIVUDINE; PHOSPHOLIPASE A2;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BIOSYNTHESIS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CATABOLISM; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CORRELATION COEFFICIENT; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; VIRUS LOAD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SYNTHESIS; HUMAN CELL; METABOLISM; PROTEIN INDUCTION;

EID: 84861471741     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201202500127     Document Type: Article

References (30)

1. Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem 1979; 254:9355-8. (Pubitemid 10248704)
2. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Cl Lab Sci 2003; 40:643-72. (Pubitemid 37491708)
3. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30:S294-301. (Pubitemid 34508006)
4. Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 2000; 80:1669-99.
5. Demopoulos CA, Karantonis HC, Antonopoulou S. Platelet activating factor - a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol 2003; 105:705-16. (Pubitemid 37533028)
6. Nomikos T, Fragopoulou E, Antonopoulou S. Food ingredients and lipid mediators. Curr Nutr Food Sci 2007; 3:255-76. (Pubitemid 350130928)
7. Tsoupras AB, Iatrou C, Frangia C, Demopoulos CA. The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets 2009; 9:390-9.
8. Gimenez R, Aguilar J. Cytidine (5-) diphosphocholine induced decrease in cerebral platelet activating factor is due to inactivation of its synthesizing enzyme cholinephosphotransferase in aged rats. Neurosci Lett 2001; 299:209-12. (Pubitemid 32124848)
9. Tsoupras AB, Chini M, Tsogas N, et al. Platelet activating factor basic metabolic enzymes in blood of naïve HIV-infected patients. Angiology 2011; Epub ahead of print.
10. Shindou H, Hishikawa D, Nakanishi H, et al. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:LYSO-PAF acetyltransferase. J Biol Chem 2007; 282:6532-9. (Pubitemid 47100867)
11. Antonopoulou S, Demopoulos CA, Iatrou C, Moustakas G, Zirogiannis P. Platelet-activating factor acetylhydrolase (PAF-AH) in human kidney. Int J Biochem 1994; 26:1157-62.
12. Doublier S, Zennaro C, Spatola T, et al. HIV-1 Tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS 2007; 21:423-32.
13. Perry SW, Hamilton JA, Tjoelker LW, et al. Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. J Biol Chem 1998; 273:17660-4. (Pubitemid 28355104)
14. Biancone L, Cantaluppi V, Boccellino M, et al. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis. Am J Pathol 1999; 155:1731-9.
15. Meltzer MS, Skillman DR, Gomatos PJ, Kalter DC, Gendelman HE. Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu Rev Immunol 1990; 8:169-94. (Pubitemid 20135625)
16. Genis P, Jett M, Bernton EW, et al. Cytokine and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 1992; 176:1703-18.
17. Lima RG, Moreira L, Paes-Leme J, et al. Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor. AIDS Res Hum Retroviruses 2006; 22:763-9. (Pubitemid 44735003)
18. Currier JS. Update on cardiovascular complications in HIV infection. Top HIV Med 2009; 17:98-103.
19. Malvestutto CD, Aberg JA. Coronary heart disease in people infected with HIV. Cleve Clin J Med 2010; 77:547-56.
20. Tsoupras AB, Chini M, Tsogas N, et al. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? AIDS Res Hum Retroviruses 2008;24:1079-86.
21. Chini M, Tsoupras AB, Mangafas N, et al. Effects of HAART on Platelet Activating Factor metabolism in naive HIV-infected patients I; Study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen. AIDS Res Hum Retroviruses 2011; Epub ahead of print.
22. Behrens GM, Reiss P. Abacavir and cardiovascular risk. Curr Opin Infect Dis 2010; 23:9-14.
23. Tsoupras AB, Chini M, Tsogas N, Mangafas N, Demopoulos CA, Lazanas MC. In vivo effects of a Ginkgo biloba extract on platelet activating factor metabolism in two asymptomatic HIV-infected patients. Eur J Inflamm 2011; 9:107-16.
24. Bradford MM. A rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.
25. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37:911-7.
26. Lundgren JD, Neuhaus J, Babiker A, et al. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-24
27. Martin A, Amin J, Cooper DA, et al. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 2010; 24:2657-63.
28. Bernatchez PN, Winstead MV, Dennis EA, Sirois MG. VEGF stimulation of endothelial cell PAF synthesis is mediated by group V 14 kDa secretory phospholipase A2. Br J Pharmacol 2001; 134:197-205. (Pubitemid 32835483)
29. Dulioust A, Vivier E, Salem P, Benvepiste J, Thomas Y. Immunoregulatory functions of paf-acether. I. Effect of paf-acether on CD4+ cell proliferation. J Immunol 1988; 140:240-5.
30. Khovidhunkit W, Memon RA, Shigenaga JK, et al. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 1999; 48:1524-31.